Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$8.70
-$0.24(-2.76%)
At close: 4:00 PM EDT
$8.70
-$0.24(-2.76%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous Close$8.46
Volume52.72K
Average Volume (3M)1.63M
Market Cap
$9.00M
Enterprise Value$5.55
Total Cash (Recent Filing)$2.77M
Total Debt (Recent Filing)$732.00K
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.50Price Target Upside227.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageAkari's minimal debt load materially lowers near-term solvency risk and preserves strategic optionality for a clinical-stage biotech. With low leverage, the company can prioritize R&D and deal-making over debt servicing, reducing bankruptcy pressure while pursuing development milestones.
Shareholder Approval For Long-term Capital AuthorityAGM approvals granting multi-year share allotment and waiver of pre-emption rights provide structural financing flexibility. This durable governance authorization enables timely equity or strategic financings, simplifying future capital raises needed to fund clinical programs without repeated shareholder reapproval.
Focused Complement-system PipelineA clear, specialized therapeutic focus on complement-mediated diseases offers a durable strategic edge: defined scientific positioning can attract specialized partners, streamline R&D decision-making, and target markets with high unmet need where successful assets can achieve lasting clinical and commercial value.
Bears Say
No Revenue; Persistent LossesAkari's pre-revenue status and sustained multi-year operating losses mean value creation depends entirely on clinical progress or external funding. Persistent negative earnings erode equity and make long-term program continuity contingent on successful trial outcomes or recurrent financing events.
Ongoing Negative Free Cash FlowConsistent negative operating and free cash flow indicates structural cash burn from development activities. Even with some improvement, continued outsized FCF deficits reduce runway, force reliance on external capital, and constrain the firm's ability to sustain or expand clinical programs without dilution or partnerships.
Dependence On Equity Financings And Dilution RiskReliance on private placements with pre-funded warrants and placement-agent ADSs shows a structural dependency on dilute equity financing. Repeated use of such transactions risks long-term shareholder dilution, disincentivizes investors, and may pressure governance and capital allocation decisions.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $9.00M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is May 20, 2027 which is in 288 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,144,588 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$28.50
▲(227.59% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors